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Individual HLA mismatches may differentially impact graft survival after kidney 
trans plantation. Therefore, there is a need for a reliable tool to define permissible 
HLA mismatches in kidney transplantation. We previously demonstrated that donor- 
derived Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA 
class II (PIRCHE-II) play a role in de novo donor-specific HLA antibodies formation 
after kidney transplantation. In the present Dutch multi-center study, we evaluated 
the possible association between PIRCHE-II and kidney graft failure in 2,918 donor–
recipient couples that were transplanted between 1995 and 2005. For these donors–
recipients couples, PIRCHE-II numbers were related to graft survival in univariate and 
multivariable analyses. Adjusted for confounders, the natural logarithm of PIRCHE-II 
was associated with a higher risk for graft failure [hazard ratio (HR): 1.13, 95% 
CI: 1.04–1.23, p = 0.003]. When analyzing a subgroup of patients who had their first 
transplantation, the HR of graft failure for ln(PIRCHE-II) was higher compared with the 
overall cohort (HR: 1.22, 95% CI: 1.10–1.34, p < 0.001). PIRCHE-II demonstrated 
both early and late effects on graft failure in this subgroup. These data suggest that 
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the PIRCHE-II may impact graft survival after kidney transplantation. Inclusion of 
PIRCHE-II in donor-selection criteria may eventually lead to an improved kidney graft 
survival.
Keywords: Pirche-ii, kidney transplantation, graft rejection, hla antigens, hla matching
inTrODUcTiOn
Kidney transplantation is the preferable treatment option for 
most patients suffering from end-stage kidney disease. Kidney 
transplantation outcome is most optimal when patient and donor 
are HLA matched (1, 2). HLA mismatches may lead to the activa-
tion of alloreactive T-cells and the development of donor-specific 
HLA antibodies (DSA), thereby significantly impairing kidney 
graft survival (3). In HLA-mismatched kidney transplantation 
graft survival decreases gradually with increasing numbers of 
mismatches on HLA-A, HLA-B, and HLA-DRB1 (2, 4). Although 
most research has been devoted to studying the impact of HLA-A, 
-B, and -DRB1 mismatching on kidney graft survival, some stud-
ies suggest that HLA-C and HLA-DQB1 may impact graft survival 
as well (5, 6). Since the role of HLA-A, HLA-B, and HLA-DRB1 
has been extensively described, the European organ exchange 
organization Eurotransplant has implemented an algorithm in 
which currently the number of HLA-A, HLA-B, and HLA-DRB1 
mismatches is taken into consideration in the allocation strategy.
HLA-matching implies that better matched kidney grafts 
(0–3 mismatches at HLA-A, -B, and -DRB1) are preferred over 
poorly matched kidney grafts (4–6 mismatches at HLA-A, -B, 
and -DRB1) (4). Since this number of HLA-A, -B, and -DRB1 
mismatches is generally calculated using low-resolution HLA 
typing (4), the actual number of HLA mismatches may even be 
higher at high-resolution level. These allelic disparities between 
donor and recipient may contribute to clinically relevant alloim-
mune responses (4). Moreover, in the current allocation strategy, 
mismatches at HLA-A, -B, and -DRB1 are regarded equally 
important. Cumulating evidence, however, suggests that each 
HLA mismatch may contribute with a different weight to graft 
survival; some HLA mismatches seem to be more permissible/
acceptable than others (7, 8). Thus, a better definition of the 
acceptable mismatches will improve graft survival.
Immunological graft rejection may originate from allo-specific 
T-cells or antibodies. T-helper cells play a role in both processes; 
on one hand, CD4+ T-helper cells can provide help to CD8+ 
cytotoxic T-cells, thereby facilitating graft-directed CD8+ T-cell 
responses. However, the mechanism of CD4+ T-cells in provid-
ing help to CD8+ T-cells remains elusive (9, 10). On the other 
hand, CD4+ T-helper cells play an essential role in HLA-specific 
antibody formation via B-cell activation and IgM-to-IgG isotype 
switching. During this process, mismatched HLA is internalized 
by B-cells, intracellularly processed, and HLA-derived epitopes 
can subsequently be loaded onto HLA class II molecules on the 
surface of B-cells. T-helper cells recognizing these HLA-derived 
epitopes drive B-cell differentiation and IgM-to-IgG isotype 
switching (11, 12). Thus, the production of HLA-specific IgG 
antibodies requires the activation of B-cells by T-helper cells. 
In this process, the T-helper cell and the B-cell recognize differ-
ent epitopes derived from the same mismatched HLA molecule, 
a phenomenon called linked recognition (13).
T-helper cell activation is antigen-specific. In HLA-mis-
matched transplantation, these T-helper cells likely recognize 
mismatched HLA epitopes in the context of HLA class II. The 
Predicted Indirectly ReCognizable HLA Epitopes presented by 
recipient HLA class II (PIRCHE-II) algorithm is able to predict 
such HLA-mismatch derived T-cell epitopes by quantifying the 
number of mismatched donor HLA-derived peptides that can be 
presented on recipients’ HLA class II molecules, designated as 
PIRCHE-II (14–16). Several studies have shown that the number 
of PIRCHE-II is related to HLA-antibody formation after preg-
nancy (15), pancreas and pancreatic islets transplantation (16), 
and kidney transplantation (17, 18). Moreover, PIRCHE-II may 
prime CD4+ T-helper cells that can provide help to cytotoxic 
CD8+ T-cells as described previously. As such, PIRCHE-II may 
affect graft rejection via both pathways. To determine whether the 
PIRCHE-II algorithm might refine the definition of permissible 
HLA mismatches in kidney transplantation, we here investi-
gated the role of PIRCHE-II in kidney graft failure. This study 
is part of the Dutch PROCARE consortium which analyzes the 
outcome of all kidney transplantations that were performed in 
the Netherlands between 1995 and 2005 and aims for improved 
matching algorithms in kidney transplantation.
MaTerials anD MeThODs
study Population
This retrospective cohort study included all kidney transplanta-
tions that were performed between 1995 and 2005 in the seven 
different Dutch transplantation centers. The flow chart of 
enrollment, inclusion, and exclusions for the study is depicted 
in Figure 1. At time of analysis, HLA typing was available for the 
majority of 6,095 kidney transplantations that were included in 
this study. For 3,488 donor–recipient couples, typing resolution 
was at serological split level or higher for HLA-A, -B, and -DRB1; 
pairs with lower resolution levels of HLA typing or no typing 
results for one or more of these loci were excluded from analyses. 
When HLA-C and HLA-DQ (beta) typing at serological split 
level was known, the typing results for these loci were also used 
as input for the PIRCHE-II and HLAMatchmaker algorithms, 
as described in the next sections. When HLA-C and HLA-DQ 
(beta) typing was not available at serological split level, typings 
for these loci were extrapolated using the method described in 
the next section.
Abbreviations: DSA, donor-specific HLA antibodies; PIRCHE-II, predicted indi-
rectly recognizable HLA epitopes presented by HLA class II; PRA, panel reactive 
activity.
FigUre 1 | Flow chart of enrollment, inclusion, and exclusions for the study.
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graft failure, death with functioning graft, and follow-up time 
was documented. The etiology of graft failures and the presence 
of DSA before transplantation were not documented. Recipients 
who never had a functioning graft after transplantation (n = 130) 
were excluded from analyses, resulting in a final cohort size of 
2,918 kidney transplantations. Informed consent for evaluation 
of clinical data was obtained from all subjects involved in the 
study. The use of clinical data of the subjects involved in this 
study was approved by the ethics committee for biobanks at the 
UMC Utrecht (TCBio; reference number: 13-633).
high-resolution extrapolation Method
Since allelic-resolution HLA typing data are unavailable for our 
cohort, we used the computational method described previously 
to calculate PIRCHE-II and eplet values using low-resolution 
HLA typing (19). Briefly, HLA haplotype frequency tables were 
used to identify the most probable allelic-resolution HLA typ-
ings from each donor and recipient low-resolution HLA typing 
(19, 20). A single low-resolution HLA typing of donor and 
recipient may result in multiple potential allelic-resolution HLA 
typings. The PIRCHE-II and eplet values for all these potential 
allelic-resolution HLA typings were calculated as described in the 
next sections. Subsequently, the PIRCHE-II and eplet values were 
weighted by multiplying the normalized frequency of a certain 
allelic-resolution HLA typing of the recipient in the population 
by the normalized frequency of a certain allelic-resolution HLA 
typing of the donor in the population. Finally, all weighted 
PIRCHE-II and eplet values were summed up, resulting in a 
decimal PIRCHE-II/eplet number.
identification of hlaMatchmaker eplets
HLAMatchmaker was used to identify three-dimensional 
polymorphic amino acid patches on the molecular surface of 
the HLA molecule to which HLA antibodies can be directed, 
designated as eplets (21–23). The number of HLAMatchmaker 
eplets was determined for each donor–recipient couple using 
HLAMatchmaker algorithm version 2.1 (available via http://
www.epitopes.net/); both antibody-verified and non-antibody-
verified eplets were taken into account. In the analyses, eplets 
that were present in the donor’s HLA and absent in the recipi-
ent’s HLA were counted as mismatched eplets. The number 
of mismatched eplets was determined via interlocus HLA 
comparisons.
identification of Pirche-ii
For all HLA mismatches, we determined the number of donor 
mismatched HLA-derived peptides that can be presented by 
recipient HLA-DRB1 (PIRCHE-II) as described previously (15). 
Briefly, the NetMHCIIpan 3.0 algorithm was used to predict the 
nonameric binding cores of donor mismatched HLA-derived 
peptides that can bind to recipient HLA-DRB1. Relevant HLA-
DRB1 binders were defined as peptides with an IC50 < 1,000 nM 
for HLA-DRB1 (17, 24). Donor-derived HLA class II binders 
that differed at least one amino acid in their nonameric bind-
ing core with the HLA sequence of the recipient were counted 
as PIRCHE-II. In the identification of PIRCHE-II, specific 
donor-epitope-HLA complexes that were present multiple times 
Donor–recipient couples with five or more mismatches at 
HLA-A, -B, and -DRB1 had an aberrant graft survival compared 
with other donor–recipient couples, suggesting that the alloca-
tions within this group were not performed according the stand-
ard Eurotransplant allocation criteria. Since we cannot correct 
for protocols performed outside the standard Eurotransplant 
allocation criteria, we excluded these donor–recipient couples 
to avoid bias (n =  297). Donor–recipient couples which were 
fully matched at serological split level HLA-A, -B, -C, -DRB1, 
and -DQB1 and had a PIRCHE-II number between 0 and 1 
(n = 143) were excluded from further analyses, as these couples 
are most likely to be fully matched at allelic-resolution level. 
These donor–recipient couples lack an immunological target 
within donor HLA and thus may have a better graft survival. 
Inclusion of these donor–recipient couples may therefore enlarge 
the PIRCHE-II effect observed in this study. Data regarding 
Table 1 | Baseline characteristics (n = 2,918).
Median recipient age, years (range) 47 (2–80)
Median donor age, years (range) 46.5 (0–79)
Recipient gender
Female, n 1,196 (41.0%)
Male, n 1,722 (59.0%)
Donor gender
Female, n 1,466 (50.2%)
Male, n 1,452 (49.8%)
Recipients with prior kidney transplantation(s), n 414
1 prior kidney transplantation, n 335
2 prior kidney transplantations, n 65
3 prior kidney transplantations, n 12
4 prior kidney transplantations, n 2
% recipients with HLA-C typing available 94.9%
% recipients with HLA-DQ typing available 98.4%
% donors with HLA-C typing available 78.2%
% donors with HLA-DQ typing available 92.5%
Median broad HLA mismatches (A/B/DR), n (IQR) 2 (1–3)
Median broad HLA-A mismatches, n (IQR) 1 (0–1)
Median broad HLA-B mismatches, n (IQR) 1 (0–1)
Median broad HLA-DR mismatches, n (IQR) 1 (0–1)
Delayed graft function, n 541 (18.5%)
Graft loss during follow-up, n 675 (23.1%)
Median follow-up time, years (IQR) 11 (8.5–14)
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in a certain donor–recipient couple were counted as a single 
PIRCHE-II. The PIRCHE algorithm is available via https://www.
pirche.org.
Since the entire amino acid sequence of relevant HLA 
molecules is required for the PIRCHE-II algorithm, incomplete 
amino acid sequences of relevant HLA molecules that were 
present in the IMGT/HLA database were extrapolated using 
a nearest-neighbor-based approach as described previously to 
obtain the complete amino acid sequences of the incomplete 
HLA allele (25). In our analyses, leader peptide sequences were 
omitted from the HLA amino acid sequences used for PIRCHE-II 
calculation.
statistical analysis
Statistical analyses were performed using SPSS Statistics soft-
ware version 21 (IBM SPSS Software). The time-dependent 
association of the HLA mismatch-related factors (i.e., the total 
number of HLA-A, -B, and -DRB1 mismatches, the number of 
mismatched eplets, and PIRCHE-II) and other covariates (donor 
age, recipient age, transplantation year, previous transplanta-
tions, and recipient immunization status) on graft function 
was univariately studied with Cox proportional hazard models. 
Recipient immunization status was based on the maximum 
panel reactive activity (PRA) percentage measured before trans-
plantation. PRA was determined by a complement dependent 
cytotoxicity (CDC) test against minimal 50 different donors 
using the basic NIH technique on unseparated peripheral blood 
mononuclear cells, which serves as a surrogate marker for the 
presence of pretransplant cytotoxic DSA. CDC was performed 
in the presence of Dithiothreitol to prevent IgM-induced false-
positive results. A PRA% of 5 was used as cutoff to distinguish 
between immunized and non-immunized recipients, according 
our generally used immunization definitions. Multivariable 
Cox proportional hazard models were constructed to identify 
variables that impact the 10-year graft survival. The models 
were constructed using forward stepwise selection consider-
ing all univariately analyzed covariates of p <  0.10. Except for 
previous transplantations and recipient immunization status, all 
covariates were used as continuous variables. For a subgroup of 
patients who had their first transplantation, additional hazard 
ratios (HRs) per PIRCHE-II were calculated at different end-
points/time points using forward stepwise selection considering 
the covariates implemented in the initial multivariable model. 
Both lost to follow-up and death with functioning graft were 
considered as censoring events in the analyses. p-Values <0.05 
were considered statistically significant.
resUlTs
baseline characteristics
The total analyzable cohort consisted of 2,918 donor–recipient 
couples. Table 1 summarizes the baseline characteristics of the 
included donor–recipient pairs. HLA-C and -DQ typing was 
available for the majority of the donor–recipient couples (HLA-C: 
78.2% for donors, 94.9% for recipients and HLA-DQB1: 92.5% 
for donors, 98.4% for recipients). The median follow-up time of 
recipients without graft failure during follow-up was 11  years. 
A total of 675 recipients (23.1% of total) experienced kidney graft 
failure during follow-up.
The number of hla-a/-b/-Drb1 
Mismatches is associated with  
graft survival
To confirm the role of HLA mismatches on transplant outcome 
in our cohort, we first investigated the relationship between the 
total number of HLA-A, -B, and -DRB1 mismatches and kidney 
graft survival. HLA-C and HLA-DQ mismatches were not 
included in these calculations, as HLA-C and HLA-DQ typing 
was not mandatory according the Eurotransplant guidelines in 
the years 1995–2005. In univariate analysis, the total number 
of HLA-A, -B, and -DRB1 mismatches was significantly associ-
ated with an increased risk for graft failure (HR: 1.11; 95% CI: 
1.04–1.18, p = 0.002, Table 2).
Pirche-ii is an independent risk  
Factor for graft Failure
Next, we investigated whether HLA mismatch-related factors 
and a set of other covariates have an influence on kidney graft 
failure. The number of PIRCHE-II was log-transformed for 
the analyses, designated as ln(PIRCHE-II), as PIRCHE-II is 
logarithmically correlated with HLA-antibody formation (17). 
In univariate analysis, ln(PIRCHE-II) was significantly associ-
ated with an increased risk of graft failure (HR: 1.15, 95% CI: 
1.06–1.25, p = 0.001; Table 2). Also the number of mismatched 
eplets was associated with an increased graft failure risk and of 
the other covariates, only recipient and donor age and previous 
transplantations were associated with graft failure (Table 2).
Table 2 | Univariate and multivariable hazard ratios (HRs) of graft failure for 
ln(PIRCHE-II), eplets, number of HLA-A, -B, and -DR mismatches, age, year of 
transplantation, retransplantation, and recipient immunization status in the overall 
cohort.
Univariate Multivariable model 
with forward stepwise 
selection
hr 95% ci p-Value hr 95% ci p-Value
ln(PIRCHE-II) 1.15 1.06–1.25 0.001 1.13 1.04–1.23 0.003
Eplets 1.01 1.00–1.01 0.01
Number of A/B/
DR mismatches
1.11 1.04–1.18 0.002
Recipient age 0.99 0.99–1.00 0.003 0.99 0.99–1.00 0.002
Donor age 1.02 1.02–1.03 <0.001 1.02 1.02–1.03 <0.001
Transplantation  
year
0.98 0.96–1.00 0.06 0.97 0.95–0.99 0.015
Previous 
transplantations
1.62 1.34–1.95 <0.001 1.56 1.29–1.89 <0.001
Recipient 
immunization 
status
1.16 0.99–1.35 0.06
A multivariable model with forward stepwise selection was generated using the 
univariate factors. Only ln(PIRCHE-II), recipient age, donor age, year of transplantation, 
and retransplantation were included in the model. Eplets, number of HLA-A, -B, 
and -DR mismatches, and recipient immunization status were not included in the 
multivariable model and, therefore, no HRs were reported for these factors.
FigUre 2 | Modeling of the increased hazard on graft failure for each Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II 
(PIRCHE-II). Based on the multivariable analyses, the kidney graft failure risk is plotted as a function of the number of PIRCHE-II for both the overall cohort and for 
the first-transplantations only group. For example for the overall cohort, a patient with a PIRCHE-II value of 2.718 [ln(2.718) = 1] has a hazard of 1.13 on kidney graft 
failure, whereas a patient with a PIRCHE-II value of 7.388 [=2.718*2.718; ln(7.388) = 2] has a hazard of 1.26 (an increase of 0.13 compared with a PIRCHE-II value 
of 2.718) on kidney graft failure. Similar calculations were performed for other PIRCHE-II values and for the first-transplantations only group. The differences in 
hazard on kidney graft failure between different PIRCHE-II values decrease for higher PIRCHE-II values.
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To further investigate the possible association between 
PIRCHE-II and kidney graft failure, a multivariable Cox regres-
sion model was constructed considering all univariately analyzed 
covariates, which allows adjustment for confounders. Recipient 
and donor age, transplantation year, previous transplantations, 
and ln(PIRCHE-II) were included in the final model (Table 2). 
The total number of HLA-A, -B, and -DRB1 mismatches, the 
number of mismatched eplets, and recipient immunization 
status did not end up in the multivariate model. ln(PIRCHE-II) 
was significantly associated with a higher risk of graft failure 
(HR: 1.13, 95% CI: 1.04–1.23, p = 0.003; Table 2). According 
to this multivariable model, for each increase of one unit 
ln(PIRCHE-II), which is equivalent to a 2.718-fold difference 
in PIRCHE-II, the risk of graft failure increases with 13%. Based 
on this multivariable analysis, we plotted kidney graft failure 
risk as a function of the number of PIRCHE-II (Figure 2). We 
observe a non-linear dose-dependent influence of the number 
of PIRCHE-II on graft failure risk. Thus, PIRCHE-II is an inde-
pendent risk factor for graft failure after kidney transplantation.
Since the presence of preformed DSA in our study cohort 
may impact our results, we next analyzed a subgroup of patients 
who had their first transplantation (n =  2,504). Since previous 
transplantations are a major cause of having pretransplant DSA, 
patients who have their first transplantation have a reduced 
chance to have clinically relevant pretransplant HLA alloim-
munization. In patients who had their first transplantation, 
ln(PIRCHE-II) was associated with a higher risk of graft failure 
(HR: 1.22, 95% CI: 1.10–1.34, p < 0.001; Table 3). In these first-
transplantation patients, the HR of graft failure for PIRCHE-II 
was higher compared with the overall cohort (Figure  2), sug-
gesting that PIRCHE-II has a higher impact on graft failure in 
first-transplantation patients.
Pirche-ii Demonstrates early and late 
effects on graft Failure
Next we investigated whether PIRCHE-II affects early or long-
term graft outcome in multivariable analyses. First we calcu-
lated the graft failure risk of ln(PIRCHE-II) at different virtual 
endpoints after transplantation in the subgroup of patients 
Table 3 | Univariate and multivariable hazard ratios (HRs) of graft failure 
for ln(PIRCHE-II), eplets, number of HLA-A, -B, and -DR mismatches, age, 
year of transplantation, and recipient immunization status in the group of first 
transplantations only.
Univariate Multivariable model with 
forward stepwise selection
hr 95% ci p-Value hr 95% ci p-Value
ln(PIRCHE-II) 1.23 1.11–1.35 <0.001 1.22 1.10–1.34 <0.001
Eplets 1.01 1.00–1.02 0.002
Number of  
A/B/DR 
mismatches
1.15 1.07–1.24 <0.001
Recipient age 1.00 0.99–1.00 0.053 0.99 0.99–1.00 0.013
Donor age 1.02 1.01–1.03 <0.001 1.02 1.02–1.03 <0.001
Transplantation  
year
0.97 0.95–1.00 0.048 0.96 0.94–0.99 0.005
Recipient 
immunization  
status
0.99 0.83–1.19 0.92
A multivariable model with forward stepwise selection was generated using 
the univariate factors. Only ln(PIRCHE-II), recipient age, donor age, and year of 
transplantation were included in the model. Eplets, number of HLA-A, -B, and -DR 
mismatches, and recipient immunization status were not included in the multivariable 
model and, therefore, no HRs were reported for these factors.
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who had their first transplantation. The HR per ln(PIRCHE-II) 
peaks around 6 months after transplantation (HR: 1.37, 95% CI: 
1.10–1.71), and afterward the HR per ln(PIRCHE-II) remains 
stable around 1.2 per ln(PIRCHE-II) (Figure 3A). Additionally, 
we investigated the kidney graft failure risk of ln(PIRCHE-II) at 
different time points after transplantation among subjects who 
did not experience graft loss before those different time points. 
Thus, for each time point, the graft survival was set to 100% 
and subsequently the HR was calculated. After an initial dip in 
the first half year, the kidney graft failure risk of ln(PIRCHE-II) 
slightly increases over time (Figure  3B). Thus, the effect of 
PIRCHE-II on kidney graft failure is most prominent around 
6  months after transplantation (Figure  3A). Our data also 
suggest that, in patients who do not reject their graft during 
this early period after transplantation, PIRCHE-II numbers 
remain associated with a higher kidney graft failure during the 
following years (Figure 3B). Thus, PIRCHE-II seems to have 
long-term effects on transplant outcome independent of the 
early effects.
DiscUssiOn
In the present study, we investigated whether the PIRCHE-II is 
related to graft survival after kidney transplantation. The total 
number of HLA-A, -B, and -DRB1 mismatches was associated 
with kidney graft survival. This observation is in line with previ-
ous observations showing that kidney graft survival gradually 
decreases when transplanted with increasing numbers of HLA 
mismatches (1, 2). We also showed that increasing PIRCHE-II 
numbers are associated with a higher risk for kidney graft failure. 
In the stepwise forward multivariable Cox regression model, 
PIRCHE-II appeared to be an independent risk factor for kidney 
graft failure. A stepwise backward multivariable Cox regression 
model showed a similar result (data not shown). Moreover, 
PIRCHE-II demonstrated both early and late effects on graft 
failure. Thus, our data support the hypothesis that the number 
of PIRCHE-II is indeed related to graft failure after kidney 
transplantation and confirm the observations of an independent 
parallel study (17). We therefore conclude that the PIRCHE-II 
classification may be a tool to identify permissible HLA mis-
matches in kidney transplantation.
Pretransplant cytotoxic DSA may have affected our observa-
tions. In the absence of pretransplant DSA data, we performed 
a subanalysis in patients who had their first transplant and, 
consequently, are less likely to have pretransplant DSA. These 
patients showed an increased HR for kidney graft failure when 
compared with the overall cohort, suggesting that previous 
transplants, as a pseudo marker for pretransplant DSA, impact 
the effect of PIRCHE-II. Similar observations were seen when 
comparing male and female subgroups separately (data not 
shown). Whether these latter observations indeed indicate a role 
for pregnancy-induced DSA or not, remains to be elucidated; 
alternative gender-related issues may influence these data. 
Additional research and validations of the pregnancy results in 
other cohorts are warranted.
Our study has several limitations. First, in the multivariable 
analysis we included HLA-mismatch-related confounders and a 
number of additional confounders. These additional confound-
ers were selected based on their available at time of analysis; only 
confounders that were validated and reliably available for most 
of the included donor–recipient couples were included in the 
analyses. However, also other factors, for example, immunosup-
pressive treatment regimen, etiology of graft loss, cold-ischemia 
time, type of donor, and transplantation center might have their 
impact on graft failure. Since some of these data are currently 
being retrospectively collected for this PROCARE cohort, fur-
ther studies are required to investigate the role of PIRCHE-II 
on graft failure in a detailed covariate analysis. Second, our cur-
rent PIRCHE-II algorithm is restricted to PIRCHE-II derived 
from HLA-A, -B, -C, -DRB1, and -DQB1 and presented by 
HLA-DRB1. However, PIRCHE-II might also be derived from 
other HLA alleles and presentation of PIRCHE-II by other HLA 
class II alleles may occur. For a major part of our study cohort, 
HLA typing of these other HLA loci is lacking. For the donor–
recipient couples with HLA typing of these additional HLA loci 
available, we were unable to extrapolate high-resolution HLA 
typings of these loci due to the absence of these loci in the 2007 
HLA haplotype frequency tables (26). Further research in dif-
ferent study cohorts is required to investigate whether addition 
of PIRCHE-II presented by or derived from these additional 
HLA loci may further improve the definition of permissible 
HLA mismatches. Third, further research on IC50 cutoff values 
may eventually lead to a more optimal method to define relevant 
HLA class II binders.
The development of de novo HLA-antibody formation is 
highly associated with a reduced 10-year graft survival (3, 27). We 
previously showed that PIRCHE-II is related to HLA-antibody 
formation (15, 16, 18). The number of PIRCHE-II indeed 
increased the chance of developing DSA and impaired kidney 
graft failure (17), suggesting that PIRCHE-II at least partly affects 
FigUre 3 | Predicted Indirectly ReCognizable HLA Epitopes presented by recipient HLA class II (PIRCHE-II) affects both early and long-term graft outcome.  
The hazard on kidney graft failure for ln(PIRCHE-II) at different virtual endpoints after transplantation is displayed in (a). Hazard ratios (HRs) and 95% CI’s were 
calculated for different virtual endpoints (1–2–3–4–5–6–9–12–18 months and 2–3–4–5–6–7–8–9–10 years after transplantation), as exemplified by the lower panel  
of (a). HRs were calculated using multivariable Cox proportional hazard models and smooth curve fitting was performed based on these data points. In the upper 
panel of (a), the solid line represents the HR and the dotted line represents the 95% CI. The kidney graft failure risks for different time spans when excluding 
subjects who experienced kidney graft failure before different time points are displayed in (b). For these analyses, the graft survival was set to 100% at each 
analyzed time point (1–2–3–4–5–6–9–12–18 months and 2–3–4–5–6–7 years after transplantation) and the HR were calculated at 10 years after transplantation,  
as exemplified in the lower panel of (b). The number of patients at risk at each analyzed time span is shown in Table S1 in Supplementary Material. Due to the low 
number of events and the limited follow-up time around 7 years after transplantation, the later time spans could not be analyzed. HR’s and 95% CI’s were calculated 
for different time spans using multivariable Cox proportional hazard models and smooth curve fitting was performed based on these data points. In the upper panel 
of (b), the solid line represents the HR and the dotted line represents the 95% CI. For both (a,b), the individual dots represent the HR’s at different virtual endpoints/
time spans. HR’s were calculated using forward stepwise selection considering the covariates implemented in the initial multivariable model [ln(PIRCHE-II), donor 
age, recipient age, and year of transplantation].
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kidney graft function indirectly via HLA-antibody formation. 
In our cohort, we were unable to investigate the effect of 
PIRCHE-II on HLA-antibody formation, since sera were not col-
lected after transplantation. In addition to driving HLA-antibody 
formation, PIRCHE-II might also induce graft failure by provid-
ing T-cell help to cytotoxic T-cells. Further research is required to 
investigate whether donor kidney HLA-derived PIRCHE-specific 
T-cells may indeed also impact kidney graft function without 
intervention of the B-cell compartment.
The PIRCHE-II associated effect on graft failure is more 
prominent in the present study than in the study of Lachmann 
et  al. (17), which might be due to differences in donor type, 
immunosuppressive treatment regimen, or additional factors 
such as cold-ischemia time between both studies. Moreover, 
a different HLA-antibody screening procedure after transplan-
tation and subsequent adaptation of the treatment regimen 
might also explain the graft survival differences. In the Dutch 
transplantation centers, regular HLA-antibody monitoring 
were not part of the routine follow-up between 1995 and 2005, 
but was performed prospectively in the German cohort. In the 
latter cohort, the immunosuppressive treatment regimen was 
adapted (intensified or changed) when HLA antibodies were 
detected, which might have reduced the risk for graft failure. 
Although future research is required to investigate the effect of 
immunosuppression adaptation after HLA-antibody detection 
on graft failure, this difference between both studies might 
explain the difference in magnitude of PIRCHE-II on graft 
failure.
High-resolution HLA typings were not yet available for 
our cohort. Therefore, we used a validated HLA extrapolation 
method to identify all possible allelic-resolution HLA typings 
for a given low-resolution HLA typing. We previously showed 
that PIRCHE-II and eplet numbers can reliably predicted for 
the majority of the donor–recipient couples using our method 
(19). The removal of HLA-C or HLA-DQ from the input slightly 
diminished the reliability of the PIRCHE-II and eplet estimations 
(19), indicating that the absence of HLA-C/HLA-DQ only 
limitedly affect the PIRCHE-II values. A subanalysis among 
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donor–recipient couples having complete HLA-A, HLA-B, 
HLA-C, HLA-DR, and HLA-DQ typing available showed a 
similar hazard on kidney graft failure for PIRCHE-II as the 
total cohort (HR: 1.13, 95% CI: 1.02–1.23, p = 0.02), indicat-
ing that the absence of HLA-C and/or HLA-DQ typing in a 
minor part of our cohort did not influence the study outcome. 
Although our approach may have resulted in an over- or 
underestimation of the exact PIRCHE-II/eplet numbers for 
certain recipient–donor combinations, the used multiple 
imputation approach is likely more reliable than selecting a 
single high-resolution HLA typing according to the most 
frequent allelic-resolution HLA haplotype in the population; 
our method does not exclude other potential allelic-resolution 
HLA haplotypes and the data were analyzed at population 
level, not at individual donor–recipient level. Importantly, 
since our multiple imputation approach has been validated 
in a Caucasian setting, further validation of the approach is 
warranted before implementing this approach in cohorts with 
a different ethnic background.
The study outcome might be biased by basing the HLA 
locus mismatch assignment on HLA-A, -B, and -DRB1 alone, 
as these typings were available for all donor–recipient couples. 
Ideally, HLA-C and -DQ also need to be included in the 
mismatch assignment. However, determining the number of 
HLA-C and -DQ mismatches via the extrapolation method 
used in our study may result in unreliable HLA mismatch 
assignment. As HLA-C and -DQ typing is now mandatory 
according the Eurotransplant guidelines, future studies will 
be able to show the impact of these loci. Further studies will 
also be required to investigate the impact of locus-specific 
PIRCHE-II scores on de novo DSA formation, as this may 
explain differential impact of individual HLA mismatches 
on graft failure. In the study of Lachmann et al. (17), the role 
of locus-specific PIRCHE-II scores on DSA formation was 
investigated. However, due to the absence of post-transplant 
DSA data, we were unable to validate these observations in 
our study.
The number of mismatched eplets is highly associated with 
DSA formation (18, 21, 27–29). Additionally, increasing num-
bers of HLA-A and HLA-B HLAMatchmaker triplet mismatches 
are associated with decreasing graft survival rates in HLA-DR 
identical kidney transplants (23). Based on these data, we imple-
mented HLAMatchmaker eplets as covariate in the analyses 
in order to avoid overestimation of the PIRCHE-II effect on 
graft failure. However, in this study we did not aim to compare 
HLAMatchmaker and the PIRCHE-II algorithm with regard 
to performance. Detailed research is required to investigate 
this aspect and also to determine whether a further refinement 
of the immunogenicity of individual eplets may improve the 
predictability of kidney graft failure in our cohort. Alternative 
approaches for estimating the humoral response toward HLA 
mismatches, such as the number of disparate amino acids or 
the physicochemical disparities (29), will be included in these 
detailed future analyses.
In conclusion, our study showed that PIRCHE-II is associated 
with graft failure after kidney transplantation. We showed that 
PIRCHE-II might be a more gradual discriminator in defining the 
permissibility of HLA mismatches. In the future, the PIRCHE-II 
algorithm might be a manner to identify mismatches that will 
have a reduced risk for kidney graft failure. Incorporating the 
PIRCHE-II algorithm in the donor-selection procedure for 
kidney transplantation may facilitate risk classification of specific 
mismatches and eventually lead to an improved graft survival. 
PIRCHE-II may be used in the donor-selection procedure in two 
ways. First, PIRCHE-II can be used to select the most optimal 
donor, thereby replacing the currently used HLA matchgrade and 
match probability. Second, in, for example, recipients receiving 
grafts from living donors, the PIRCHE-II algorithm can also be 
used for assessing the risk for graft failure before transplantation. 
Patients who are at higher risk for kidney graft failure due to a high 
PIRCHE-II score might benefit from more intense immunosup-
pression or can be monitored more closely after transplantation.
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